Strategic Investment from Nant Capital
A $12 million strategic loan commitment from Nant Capital, consisting of two tranches of convertible promissory notes, demonstrating confidence in Panbela's multi-targeted approach to pancreatic cancer treatment.
ASPIRE Trial Progress
The Phase III ASPIRE global clinical trial for metastatic pancreatic ductal adenocarcinoma is showing a notably lower event rate, potentially signaling better patient outcomes and a significant advance over current standards of care.
Eflornithine FDA Approval
Eflornithine received FDA approval, marking the first FDA-approved polyamine-targeted therapy in cancer, validating Panbela's polyamine-focused approach.
Advancements in Clinical Pipeline
Progress in Phase II and Phase I trials, including the eflornithine study in prostate cancer and the initiation of a study for STK11 mutant non-small cell lung cancer.